Monopar Therapeutics Inc (MNPR)

NASDAQ
1.790
-0.010(-0.56%)
  • Volume:
    4,826
  • Day's Range:
    1.710 - 1.840
  • 52 wk Range:
    1.702 - 6.980
Unusual Pre-Market activity today

MNPR Overview

Prev. Close
1.8
Day's Range
1.71-1.84
Revenue
-
Open
1.84
52 wk Range
1.702-6.98
EPS
-0.822
Volume
4,826
Market Cap
22.78M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
8,298
P/E Ratio
-2.25
Beta
0.472
1-Year Change
-64.69%
Shares Outstanding
12,725,751
Next Earnings Date
Nov 17, 2022
What is your sentiment on Monopar Therapeutics?
or
Market is currently closed. Voting is open during market hours.

Monopar Therapeutics Inc Company Profile

Monopar Therapeutics Inc Company Profile

Employees
10

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to potentially treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was incorporated in 2014 and is headquartered in Wilmette, Illinois.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesSellSellSellStrong SellStrong Sell
Technical IndicatorsStrong SellStrong SellStrong SellStrong SellStrong Sell
SummaryStrong SellStrong SellStrong SellStrong SellStrong Sell
  • The market looks good after the cabinet got ahold of the world, lol!
    0
    • https://seekingalpha.com/pr/18243773-sellas-life-sciences-reports-full-year-2020-financial-results-and-provides-business-update
      0
      • any news?
        1
        • news?
          0
          • Sky Rocket
            0
            • Buy buy buy going up all the way to 40$
              0
              • anyone here?
                0
                • its a 100%buy...prediction $42.00 high and a.low of 40.00 when
                  0
                  • its a 100%buy...prediction $42.00 high and a.low of 40.00 when....
                    0
                    • keep going
                      0